These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35132205)

  • 1. Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy.
    Fonck C; Su C; Arens J; Koziol E; Srimani J; Henshaw J; Van Tuyl A; Chandra S; Vettermann C; O'Neill CA
    Gene Ther; 2023 Aug; 30(7-8):581-586. PubMed ID: 35132205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
    Zhang L; Handyside B; Murphy R; Sihn CR; Xie L; Vitelli C; Harmon D; Sisó S; Liu S; Bullens S; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2020 Jun; 17():13-20. PubMed ID: 31890737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
    Fong S; Yates B; Sihn CR; Mattis AN; Mitchell N; Liu S; Russell CB; Kim B; Lawal A; Rangarajan S; Lester W; Bunting S; Pierce GF; Pasi KJ; Wong WY
    Nat Med; 2022 Apr; 28(4):789-797. PubMed ID: 35411075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers.
    Sihn CR; Handyside B; Liu S; Zhang L; Murphy R; Yates B; Xie L; Torres R; Russell CB; O'Neill CA; Pungor E; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2022 Mar; 24():142-153. PubMed ID: 35036471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood.
    Zhang L; Yates B; Murphy R; Liu S; Xie L; Handyside B; Sihn CR; Bouwman T; Galicia N; Tan D; Fonck C; Arens J; Clark A; Zhang W; Chandra S; Srimani J; Holcomb J; Van Tuyl A; Henshaw J; Vettermann C; Siso S; Su C; Bullens S; Bunting S; O'Neill C; Fong S
    Mol Ther Methods Clin Dev; 2022 Sep; 26():519-531. PubMed ID: 36092364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Prednisolone Promotes AAV5 Hepatocyte Transduction Through the Novel Mechanism of AAV5 Coreceptor Platelet-Derived Growth Factor Receptor Alpha Upregulation and Innate Immune Suppression.
    Handyside B; Zhang L; Yates B; Xie L; Ismail AM; Murphy R; Baridon B; Su C; Bouwman T; Mangini L; Tahquechi J; Salcido S; Minto WC; Keenan WT; Ntai I; Sihn CR; Bullens S; Bunting S; Fong S
    Hum Gene Ther; 2024 Jan; 35(1-2):36-47. PubMed ID: 38126359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
    Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
    Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A.
    Greig JA; Smith MK; Nordin JML; Goode T; Chroscinski EA; Buza EL; Schmidt N; Kattenhorn LM; Wadsworth S; Wilson JM
    Hum Gene Ther; 2022 Apr; 33(7-8):421-431. PubMed ID: 34652966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer.
    Sandza K; Clark A; Koziol E; Akeefe H; Yang F; Holcomb J; Patton K; Hammon K; Mitchell N; Wong WY; Zoog SJ; Kim B; Henshaw J; Vettermann C
    Gene Ther; 2022 Feb; 29(1-2):94-105. PubMed ID: 34421119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained expression of human factor VIII in mice using a parvovirus-based vector.
    Chao H; Mao L; Bruce AT; Walsh CE
    Blood; 2000 Mar; 95(5):1594-9. PubMed ID: 10688813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice.
    Ismail AM; Witt E; Bouwman T; Clark W; Yates B; Franco M; Fong S
    Mol Ther Methods Clin Dev; 2024 Sep; 32(3):101294. PubMed ID: 39104575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of
    Liu S; Razon L; Ritchie O; Sihn CR; Handyside B; Berguig G; Woloszynek J; Zhang L; Batty P; Lillicrap D; Agrawal V; Cortesio C; Gebretsadik K; Akeefe H; Colosi P; Kim B; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2022 Sep; 26():61-71. PubMed ID: 35782594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.